Find the Perfect Plan for Your Investment Journey
Last Price
52 Week Range
$3.81 - $19.71
Next Earnings Date
May 01 2025
Next Earnings Date
May 01 2025
Last Price
Market Cap | $298.13M |
EV | $555.81M |
Shares Outstanding | 68.38M |
Beta | 0.35 |
Analyst Rating | BUY |
Analyst Target Price | $20.88 |
P/E 2025E | - |
P/Revenue 2025E | 1.82x |
Revenue | - |
EPS | -10.80% |
Operating Cash Flow | -21.50% |
Free Cash Flow | -18.00% |
Revenue | 120.40% |
EPS | - |
Operating Cash Flow | - |
Free Cash Flow | - |
Gross Margin 2025E | 82.68% |
Net Profit Margin 2025E | -185.06% |
ROE 2025E | - |
ROCE 2024 | - |
DPS 2025E | $0.00 |
Payout Ratio 2025E | 0.00% |
Div. Yield 2025E | 0.00% |
DPS Last 3Y CAGR | - |
Price
%
1M
3M
6M
1Y
3Y
5Y
Phathom Pharmaceuticals, Inc.
PHAT
Sector
Healthcare
Industry
Biotechnology
CEO
Curran, Terrie
Employees
427
Website
www.phathompharma.comIPO Date
2019-10-25
Headquarters
100 Campus Drive, Suite 102, Florham Park, New Jersey, 07932, United States
COMPANY
NEWSLETTER
© Copyright 2025, All Rights Reserved